Role of [D.sub.1]/[D.sub.2] dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats.
Opioids are highly efficacious analgesic drugs. However, repeated use of these drugs leads to the development of tolerance, thereby limiting their effectiveness and usage. The mechanisms underlying opioid tolerance are not entirely understood. Up to the present, several studies carried out on the mechanism of morphine tolerance. It has been shown that NMDA receptors  and cannaboid receptors  are involved in tolerance to opiate-induced antinociception. Tang et al.  reported that [Ca.sup.2+]/calmodulin-dependent protein kinase II (CaMKII) can modulate opioid tolerance and dependence via its action on learning and memory. Furthermore, it has been suggested that transient receptor potential vanilloid-1 (TRPV1) plays a critical role in morphine tolerance . Recently, we demonstrated that the serotonergic [5, 6] and noradrenergic system  play a significant role in the morphine tolerance. The opioid system has close functional links to the dopaminergic system in several brain areas, including the substantia nigra , striatum, and mesolimbic projections . Opioids are known to modulate dopamine release in a variety of brain areas . Moreover, some properties of opioids, including hyperlocomotion and reward, are at least partly mediated through dopamine receptors , and morphine is reported to increase the metabolism of dopamine in the septum and nucleus accumbens . Dopamine has been implicated in the development of tolerance and dependence to opioids . It has been demonstrated that activation of opioid receptors located on dopaminergic neurones in the striatum and nucleus accumbens may play an important role in mediating tolerance and sensitization to opiates . Dopamine exerts its action by binding to its specific membrane receptors (DA-Rs) which are subdivided into two subfamilies, D1-and D2-like, on the basis of their biochemical and pharmacological properties [15,16]. The Di-like subfamily comprises D1-and D5-R, while the D2-like subfamily includes D2-, D3-and D4-R . The two DA-R subfamilies differentially couple to adenylate cyclase  and exert different effects in many conditions . Dopamine regulates the two major striatal neuronal pathways through differential dopamine receptors. It regulates the striatonigral neurons via D1-dopamine receptors but regulates the striatopallidal neurons via D2-dopamine receptors . In the striatum, dopaminergic and opioidergic neurons display interactions in regulating the function of efferent striatal neurons. For example, morphine acutely increases dopamine release in caudate putamen and nucleus accumbens . Therefore, the D1-like dopamine receptor antagonist SCH 23390 can block a short-term morphine-induced increase in c-fos expression in the nucleus accumbens and caudate putamen . Accordingly, it has been shown that D1-and D2-like dopamine receptors have opposing influences on morphine-induced antinociception . D2-like dopamine receptors, but not the D1-dopamine receptor, exert antinociceptive effects and have a potentiating effect on morphine anti-nociception . However, the effect of D2-dopamine receptors on the expression of morphine tolerance has not been elucidated. Perphenazine has been used in clinical practice as antipsychotic drugs for more than 60 years, and appears to induce their effects by acting as dopamine receptor antagonist . In this study, we examined effects of D1/D2 dopamin receptors antagonist perphenazine on morphine analgesia and tolerance using the tail-flick and hot-plate tests in rats. In addition, we compared separately the roles of D1-and D2-dopamin receptor in these effects of perphenazine using D1-dopamine receptor antagonist SCH 23390 and D2-dopamine receptor antagonist eticlopride.
MATERIALS AND METHODS
Wistar Albino rats (weighing 190-205 g) were obtained from the Laboratory Animal Center, Cumhuriyet University School of Medicine (Sivas, Turkey). Rats were maintained under standard conditions: 12-h light-dark schedule (lights on at 8:00 A.M.) with ad libitum food and water and constant temperature (22 [+ or -] 2[degrees]C). All experiments were carried out blindly between 09:00 and 17:00 h. Procedures and animal handling met the guidelines of the National Institutes of Health detailed in the "Principles of animal laboratory care". The experimental protocols were approved by the Cumhuriyet University Animal Ethics Committee (Licence number: 87/Ethic).
Morphine sulphate (Cumhuriyet University Hospital, Turkey), perphenazine, SCH 23390 and eticlopride (Sigma Chemical Co., St. Louis, MO) were dissolved in physiological saline. Solutions were freshly prepared on the days of experimentation. Subcutaneous (s.c.) morphine (5mg/kg), perphenazine (1, 5, and 10 mg/kg; i.p.), SCH 23390 (1 mg/kg; i.p.), eticlopride (1 mg/kg; i.p.) were administered before the analgesia tests.
Induction of morphine tolerance
The animals were rendered tolerant to morphine using the method by a previous study on the induction of morphine tolerance . For tolerance induction, groups of 7-8 rats were randomly chosen and treated subcutaneously (s.c.) with morphine 50 mg/kg, once a day for 3 days. To evaluate the degree of tolerance, the analgesic effect of the test doses of morphine (5 mg/kg, s.c.) were measured by the hot-plate and tail-flick tests 24 h after the last morphine injection (day 4). In addition, to determine effects of perphenazine, SCH 23390 and eticlopride on the morphine tolerance, morphine applied with perphenazine, SCH 23390 and eticlopride to the morphine tolerant animals on day 4.
We used a standardised tail flick apparatus (May TF 0703 Tail-flick Unit, Commat, Turkey) to evaluate thermal nociception. The radiant heat source was focused on the distal portion of the tail at 3 cm after administration of the vehicle and study drugs. Following vehicle or compound administration, tail-flick latencies (TFL) were obtained. The infrared intensity was adjusted so that basal TFL occurred at 2.8 [+ or -] 0.4 s. Animals with a baseline TFL below 2.4 or above 3.2 s were excluded from further testing. The cutoff latency was set at 15 s to avoid tissue damage. Any animal not responding after 15 s was excluded from the study. The hyperalgesic response in the tail-withdrawal test is generally attributed to central mechanisms [26, 27].
The antinociceptive response on the hot-plate is considered to result from a combination of central and peripheral mechanisms (26). In this test, animals were individually placed on a hot-plate (May AHP 0603 Analgesic Hot-plate Commat, Turkey) with the temperature adjusted to 54 [+ or -] 3[degrees]C. The latency to the first sign of paw licking or jump response to avoid the heat was taken as an index of the pain threshold; the cut-off time was 30 s in order to avoid damage to the paw.
The analgesic effects of perphenazine, SCH 23390, eticlopride, and morphine were considered at 30-min intervals (0, 30, 60, 90, and 120 min) by tail-flick and hot-plate test in rats. To evaluate the effects of perphenazine, SCH 23390, and eticlopride on development of morphine tolerance, morphine tolerant animals received perphenazine (1, 5 and 10 mg/kg), SCH 23390 (1 mg/kg), and eticlopride (1 mg/ kg). In the saline-treated group, animals received saline (10 ml/kg) instead of morphine during the induction session.
[FIGURE 1 OMITTED]
In order to calculate % maximal antinociceptive effects (% MPE), tail-flick and hot-plate latencies (in seconds) were converted to percent antinociceptive effect using the following equation: % MPE = [(Postdrug latency-Baseline latency) / (Cutoff value -Baseline latency)] x 100.
All experimental results were expressed as mean [+ or -] SEM (standard error of mean). The effect of antinociception was measured and the mean of % MPEs in all groups was calculated. The data were analysed by analysis of variance followed by Tukey test. A significant difference was defined as a p value <0.05.
[FIGURE 2 OMITTED]
The analgesic effects of different doses of perphenazine
To determine the effective dose of perphenazine, the analgesic response were measured for the three different doses of perphenazine (1, 5, and 10 mg/kg) at 30-min intervals (0, 30, 60, 90, and 120 min) by the analgesia tests. The maximum analgesic effect was observed at 60 min after administration 10 mg/kg dose of perphenazine (27.9 [+ or -] 5.2 for tail-flick and 26.4 [+ or -] 4.8 for hot-plate test). The % MPE produced by perphenazine (10 mg/kg) was significantly higher than in the other groups (1 mg/kg, 5 mg/ kg perphenazine, and saline group) in both tail-flick test (p<0.01; Figure 1A) and hot-plate test (p<0.01; Figure 1B). Effect of perphenazine on morphine analgesia Statistical analysis indicated that pretreatment of animals with perphenazine significantly increased morphine analgesic effect in both tail-flick (p<0.05; Figure 2A) and hot-plate test (p<0.05; Figure 2B) compared to morphine administration group. The peak value of this group was observed at 60 min after administration of morphine and perphenazine in analgesia tests (tail-flick: 52.3 [+ or -] 4.6 and hot-plate: 59.3 [+ or -] 4.9).
[FIGURE 3 OMITTED]
[FIGURE 4 OMTTED]
[FIGURE 5 OMTTED]
Effect of eticlopride on morphine analgesia
The findings demonstrated that D2-dopamin receptor antagonist eticlopride significantly increased morphine analgesic effect in tail-flick (p<0.05; Figure 3A) and hotplate test (p<0.05; Figure 3B) compared to morphine administration group. The peak value of this group was also observed at 60 min after administration of morphine in analgesia tests (tail-flick: 59.3 [+ or -] 4.7 and hot-plate: 65.2 [+ or -] 4.8). Furthermore, these data suggested that eticlopride alone has a significant analgesic effect compared to the saline group.
Effect of SCH23390 on morphine analgesia
Systemic administration of SCH 23390 (Di-dopamin receptor antagonist) with morphine did not significantly increase in % MPE in both the tail-flick (Figure 4A) and hot-plate (Figure 4B) assays as compared to morphine group rats. Also, SCH 23390 alone had no a significant analgesic effect compared to the saline treatment group rats.
Effects of perphenazine, eticlopride, and SCH 23390 on tolerance to the morphine antinociception
Perphenazine and eticlopride in combination with morphine produced a significant decrease (increase in % MPE value) morphine tolerance in both the tail-flick (p<0.01, for perphenazine and p<o.05, for eticlopride; Figure 5A) and hot-plate assays (p<0.01, for perphenazine and p<0.05, for eticlopride; Figure 5B) as compared to the morphine tolerant rats. On the contrary, Di-receptor antagonist SCH 23390 in combination with morphine produced no significant effect on morphine tolerance in the tail-flick (Figure 5A) and hot-plate assays (Figure 5B) as compared to the morphine tolerant rats. The maximum % MPE was observed at 60 min after administration of morphine by analgesia tests in all groups rats.
In the present study, blockade of D1-and D2-dopamine receptors by perphenazine led to a decreased degree of tolerance to morphine-induced antinociception. Likewise, selective D2-dopamine receptor antagonist eticlopride produced a significant decrease morphine analgesic tolerance. In contrast, D1-dopamine receptor antagonist SCH 23390 in combination with morphine did not significantly decrease morphine tolerance. These findings demonstrate that D2-dopamine receptor has an important role rather than D1-dopamine receptor in morphine analgesic tolerance. The last two decades, many mechanisms have been proposed about the development of morphine tolerance. Recently, one of the discussed topics is the dopaminergic system on the analgesia. Initially, the analgesic effect is caused by inhibition of dopamine receptors . Accordingly, our findings indicate that D1/D2 dopamine receptor antagonist perphenazine and D2-dopamin receptor antagonist eticlopride showed a significant analgesic effect in analgesia tests. The interaction between the dopamine and opiate systems is well recognized . Considerable evidence suggests that dopamine activity affects the opioid system by modulating opiate peptide transcripts , synthesis , release, and biotransformation . In contrast, opioids modulate the dopamine system by several mechanisms, such as dopamine synthesis , release , biotransformation , and activity of dopaminergic neurons . It has been reported that there is functional interrelationship between morphine and the dopaminergic system [37, 38]. Locomotion induced by morphine  and changes in temperature  may be mediated via the dopaminergic system. Furthermore, the dopaminergic system also has been implicated in the antinociceptive effect and in the expression of signs of morphine withdrawal . It seems that mesolimbic dopaminergic pathway is essential in the sensitization process. For example, it has been shown that dopamine alters the acquisition of sensitization to the motor effects of morphine in mice . It has been suggested that D2-dopamine receptor antagonist sulpiride decreased the response to morphine (6 and 9 mg/kg) in the formalin test, whereas SCH 23390 did not influence the antinociception induced by morphine . In contrast, our data demonstrated that D2-dopamine receptor antagonist eticlopride significantly increased morphine analgesic effect in the analgesia tests. In addition, several studies have demonstrated that CaMKII has a critical role in opioid tolerance and dependence [44, 45]. Supraspinal and spinal inhibition of CaMKII not only prevented but also reversed opioid-antinociceptive tolerance and physical dependence in several rodent models [3, 45]. Furthermore, it has been reported that dopamin receptor antagonist haloperidol attenuates opioid tolerance and dependence by suppressing CaMKII activity . These data support a critical role of CaMKII in the development and maintenance of opioid tolerance. It has been suggested that cAMP-dependent protein kinase (PKA) signal pathway was involved in dopamine-mediated change of [Na.sup.+], [K.sup.+]-ATPase activity after short-term or long-term morphine treatment . Opioid and D2-dopamine receptors both couple to inhibitory G protein (Gi/o). Activation of both receptors by their agonists inhibits adenylyl cyclase and decreases PKA activation, leading to an enhancement of [Na.sup.+], [K.SUP.+]-ATPase activity. Eticlopride only reverses D2- receptor-mediated increase in [Na.sup.+], [K.SUP.+]-ATPase activity. Opioid receptor antagonist naltrexone reversed both short-term and long-term morphine-induced changes of [Na.sup.+], [K.SUP.+]-ATPase activity. These results suggest that D2-dopamine receptors are implicated in regulating striatal [Na.sup.+], [K.SUP.+]-ATPase activity after shorterm morphine treatment, whereas D1-dopamine receptors are involved in regulating striatal [Na.sup.+], [K.SUP.+]-ATPase activity upon long-term morphine treatment. Involvement of dopamine receptors in regulating [Na.sup.+], [K.SUP.+]-ATPase activity in vivo by morphine is further supported by the observation that eticlopride failed to suppress the enhancement of [Na.sup.+], [K.SUP.+]-ATPase activity induced by in vitro direct administration of morphine to isolated striatal synaptosomes . Dopamine is a general dopamine receptor agonist and activates both Di and D2 dopamine receptors. Activation of D2 dopamine receptors stimulates [Na.sup.+], [K.SUP.+]-ATPase activity , whereas activation of Di dopamine receptors inhibits [Na.sup.+], [K.SUP.+]-ATPase activity . This dopamine-PKA signal pathway may explain the mechanism of tolerance to morphine. In the same way, dopamin receptor antagonist perphenazine may decrease tolerance to morphine by means of D2-receptor.
Results from the present study suggested that dopamine receptors play a significant role in the morphine analgesic tolerance. In particular, D2-dopamine receptor has an important role rather than Di-dopamine receptor in development tolerance to morphine. The most important limitation of this study is no adequate data on human study. In the future, dopamin D2-receptor antagonist perphenazine may be used to decrease the development of tolerance to morphine. However, further investigation is needed to explain the mechanism of morphine tolerance.
This study was supported by Cumhuriyet University Scientific Research Project (CUBAP, Project Number T-329).
DECLARATION OF INTEREST
The authors declare no conflicts of interest in relation to this article.
 Mendez IA, Trujillo KA. NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology 2008; 196:497-509.
 Fischer BA, Ward SJ, Henry FE, Dykstra LA. Attenuation of morphine antinociceptive tolerance by a CBi receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropharmacology 2010; 58:544-550.
 Tang L, Shukla PK, Wang LX, Wang ZJ. Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of CaThcalmodulin-dependent protein kinase II. J Pharmacol Exp Ther 2006; 317:901-909.
 Chen Y, Geis C, Sommer C. Activation of TRPV1 contributes to morphine tolerance: Involvement of the mitogen-activated protein kinase signaling pathway. The J Neurosci 2008; 28:5836-5845.
 Ozdemir E, Bagcivan I, Gursoy S, Altun A, Durmus N. Effects of fluoxetine and LY 365265 on tolerance to the analgesic effect of morphine in rats. Acta Physiol Hung 2011; 98:205-213.
 Ozdemir E, Gursoy S, Bagcivan I. The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. J Physiol Sci 2012; 62:317-323.
 Gursoy S, Ozdemir E, Bagcivan I, Altun A, Durmus N. Effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats. Ups J Med Sci 2011; 116:238-246.
 Llorens-Cortes C, Pollard H, Schwartz JC. Localization of opiate receptors in substantia nigra: evidence by lesion studies. Neurosci Lett 1979; 12:165-170.
 Wu Z-Q, Chen J, Chi Z-Q, Liu J-G. Involvement of dopamine system in regulation of [Na.sup.+],[K.SUP.+]-ATPase in the striatum upon activation of opioid receptors by morphine. Mol Pharmacol 2007; 71:519-530.
 Wise RA. Neurobiology of addiction. Curr Opin Neurobiol. 1996; 6(2)243-251.
 Lu L, Su WJ, Yue W, Ge X, Su F, Pei G. et al. Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a sero tonin and noradrenaline reuptake inhibitor. Life Sci. 2001; 69(1)3746.
 Wood PL. Opioid regulation of CNS dopaminergic pathways: a review of methodology, receptor types, regional variations and species differences. Peptides. 1983; 4(5)395-601.
 Johnson DW, Glick SD. Dopamine release and metabolism in nucleus accumbens and striatum of morphine tolerant and nontolerant rats. Pharmacol Biochem Behav 1993; 46:341-347.
 Goodman RR, Aider BA, Pasternak GW. Regional distribution of opioid receptors. In: Pasternak GW (ed.), The opiate receptors, Humana Press, New York 1988; 197-228.
 Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16:299-321.
 Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24:125-132.
 Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci 2000; 23: 34-40.
 Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277:93-96.
 Le Moine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol. 1995; 355(3):418-426.
 Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 1991; 566:348-350.
 Bontempi B, Sharp FR. Systemic morphine-induced c-Fos protein in the rat striatum and nucleus accumbens is regulated by mu opioid receptors in the substantia nigra and ventral tegmental area. J Neurosci 1997; 17:8596-8612.
 Zarrindast MR, Moghaddampour E. Opposing influences of D-1 and D-2 dopamine receptors activation on morphine-induced antinociception. Arch Int Pharmacodyn Ther. 1989;300:37-50.
 Barasi S, Duggal KN. The effect of local and systemic application of dopaminergic agents on tail flick latency in the rat. Eur J Pharmacol 1985; 117:287-294.
 Marder SR. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry. Philadelphia: W.B. Saunders 2008; 1569-1585.
 Zarrindast MR, Dinkoub Z, Homayoun H, Bakhtiarian A, Khavandgar S. Dopamine receptor mechanism(s) and morphine tolerance in mice. J Psychopharmacol. 200246(3)261-266.
 Kanaan SA, Saade NE, Haddad JJ, Abdelnoor AM, Atweh SF, Jabbur SJ, Safieh-Garabedian B. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain. 1996; 66(2-3)373-379.
 Ramabadran K, Bansinath M, Turndorf H, Puig MM. The hyperalgesic effect of naloxone is attenuated in streptozotocin-diabetic mice. Psychopharmacology (Berl.) 1989; 97:169-174.
 Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:78-97.
 Unterwald EM, Cuntapay M. Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction. Neuropharmacology. 2000; 39(3)372-381.
 Morris BJ, Hunt SP. Proenkephalin mRNA levels in rat striatum are increased and decreased, respectively, by selective D2 and D1 dopamine receptor antagonists. Neurosci Lett 1991; 125:201-204.
 Voorn P, Docter GJ, Jongen-Relo AL, Jonker AJ. Rostrocaudal subregional differences in the response of enkephalin, dynorphin and substance P synthesis in rat nucleus accumbens to dopamine depletion. Eur J Neurosci 1994; 6:486-496.
 Terashvili M, Wu HE, Schwasinger ET, Hung KC, Hong JS, Tseng LF. (+)-Morphine attenuates the (-)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated dopamine increase in the posterior nucleus accumbens of the rat. Eur J Pharmacol 2008; 587:147-154.
 Alper RH, Demarest KT, Moore KE. Morphine differentially alters synthesis and turnover of dopamine in central neuronal systems. J Neural Transm 1980; 48:157-165.
 Devine DP, Leone P, Pocock D, Wise RA. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 1993; 266:1236-1246.
 Yonehara N, Clouet DH. Effects of delta and mu opiopeptides on the turnover and release of dopamine in rat striatum. J Pharmacol Exp Ther 1984; 231: 38-42.
 Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12:483-488.
 Chartoff EH, Mague SD, Barhight MF, Smith AM, Carlezon WA. Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci 2006; 26:6450-6457.
 Rezayof A, Amini R, Rassouli Y, Zarrindast MR. Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents. Physiol Behav 2006; 88:124-131.
 Zarrindast MR, Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D1 and D2 receptor involvement. Gen Pharmacol 1992; 23:1221-1225
 Weiss J, Thompson ML, Shuster L. Effects of naloxone and naltrexone on drug-induced hypothermia in mice. Neuropharmacology. 1984; 23(5): 483-489.
 Dizgah IM, Karimian SM, Zarrindast MR, Sohanaki H. Attenuation of morphine withdrawal signs by a D1-receptor agonist in the locus coeruleus of rats. NeuroReport 2005; 16:1683-1686.
 Kuribara H. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur J Pharmacol. 1995; 275(3)251-258.
 Zarrindast M-R, Asgari-Afshar A, Sahebgharani M. Morphine-induced antinociception in the formalin test: sensitization and interactions with D1 and D2 dopamine receptors and nitric oxide agents. Behav Pharmacol 2007; 18:177-184.
 Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci 2006; 79:1681-1691.
 Wang ZJ, Tang L, Xin L. Reversal of morphine antinociceptive tolerance by acute spinal inhibition of [Ca.sup.2+]/calmodulin-dependent protein kinase II. Eur J Pharmacol 2003; 465:199-200.
 Yang C, Chen Y, Tang L, Wang ZJ. Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence. J Pharmacol Exp Ther. 2011;338(1):164-172.
 Wu Z-Q, Li M, Chen J, Chi Z-Q, Liu J-G. Involvement of cAMP/ cAMP-dependent protein kinase signaling pathway in regulation of [Na.sup.+],[K.SUP.+]-ATPase upon activation of opioid receptors by morphine. Mol Pharmacol. 2006;69:866-876.
 Yamaguchi I, Walk SF, Jose PA, Felder RA. Dopamine D2L receptors stimulate [Na.sup.+]/K([sup.+])-ATPase activity in murine LTK-cells. Mol Pharmacol. 1996; 49(2): 373-378.
 Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A. et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998;281(5378):838-842.
Submitted: 14 December 2012 / Accepted: 27 January 2013
Ercan Ozdemir (1) *, Ihsan Bagcivan (2), Sinan Gursoy (3)
(1) Department of Physiology, School of Medicine, Cumhuriyet University, Yenijehir st, 58140 Sivas, Turkey. (2) Department of Pharmacology, School of Medicine, Cumhuriyet University, Yenijehir st, 58140 Sivas, Turkey. (3) Department of Anesthesiology and Reanimation, School of Medicine, Cumhuriyet University, Yenijehir st, 58140 Sivas, Turkey.
* Corresponding author: Ercan Ozdemir, Department of Physiology, School of Medicine, Cumhuriyet University, Yenijehir st, 58140 Sivas, Turkey Phone: +90 346 219 1602 Fax: +90 346 219 1602 e-mail: email@example.com
|Printer friendly Cite/link Email Feedback|
|Author:||Ozdemir, Ercan; Bagcivan, Ihsan; Gursoy, Sinan|
|Publication:||Bosnian Journal of Basic Medical Sciences|
|Date:||May 1, 2013|
|Previous Article:||Effect of interferon-[gamma] on NF-[kappa]B and cytokine IL-18 and IL-27 in acute pancreatitis.|